The Most Up-to Date Microsoft070-411Exam Questions 700-505 700-501 648-232 640-911 070-462 3I0-012 070-463 Latest117-202Questions - LPIC Level 2 117-202 Certification RCDD-001 070-685 200-101 070-412 Download Cisco400-101Exams - Free VCE Exams For All 70-243 200-120 100-105 Latest 117-201 Questions - LPIC Level 2 117-201Certification C9530-404 070-480 70-487 300-207 4A0-100 600-199 350-018 070-410 100-101 CCNP Routing and Switching SWITCH300-115Official Cert M70-201 C2020-703 070-347 70-412 70-417 JN0-643 E20-690 70-410 642-747 70-331 70-413 Pass MICROSOFT70-411exam - test questions 352-001 210-260 SY0-401 200-125 300-320 200-310 CISSP PMP 300-075 210-065 Cisco CCNA Collaboration210-060CICD: Welcome to Cisco 70-534 70-532 EX200 1Z0-803 210-451 300-101 Latest HP0-S42 Questions - ASEHP0-S42Certification 300-206 070-346 70-461 HP0-S41 640-916 CompTIA Network+N10-006 EX300 1Z0-434 1Z0-060 C_HANAIMP151 C_TAW12_740 AWS-SYSOPS 70-346 2V0-620 300-070 C_HANATEC151 LatestE05-001Questions - Cloud Architect (EMCCA) JN0-360 2V0-641 642-999 70-697 300-208 FC0-U51 Latest PW0-071 Questions - CWTS PW0-071Certification C_GRCAC_10 IIA-CIA-PART3 642-732 500-260 C_HANAIMP142 98-366 1Z0-047 70-496Microsoft Real Exam Questions - 100% Free VCE Files 70-533 810-403 642-998 70-470 JN0-343 CCNP Wireless642-742New Updated Cisco 642-742 Study 220-802 70-486 642-035 JN0-692 1Z0-470 CAS-002 Cisco 642-883 Dumps |642-883Exam Questions PGMP 200-105 1Z0-051 642-887 070-688 156-215.77 400-351 H12-211Exam Huawei H12-211 Test Questions PDF C2090-930 102-400 70-696 SK0-004 101-400 1Z0-061 ADM-211 300-360 CCNP Data Center642-996Latest Version Cisco 642-996 With New 400-051 70-646 4A0-107 1Z0-574 74-343 700-039 1Z0-435Oracle Business Process Management Suite 1Y0-401 1Y0-201 200-355 74-344 300-135 Download300-370Exam PDF Questions Answers 712-50 070-496 C2090-311 300-080 640-875 AX0-100Axis Communications Real Exam Questions

BPH program overview

About BPH

Benign prostatic hyperplasia (BPH or enlarged prostate) is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. Despite available pharmaceutical treatments and surgical options, no single solution provides quick, long-term relief of symptoms without unwanted side effects.

What is BPH?

Benign prostatic hyperplasia (BPH) is an enlarged prostate gland often resulting in a constricted or partially blocked urethra that can lead to pain, discomfort and other complications with urinating.
BPH, and its associated clinical manifestations of Lower Urinary Tract Symptoms (LUTS), is one of the most common medical conditions of aging men in the United States, with approximately 70% of men aged 60-69 years and 80% of men older than the age of 70 being affected by BPH. If untreated, it can lead to urinary problems such as:

  • Trouble starting and stopping urination
  • Frequent and irregular needs to urinate, particularly in the night while sleeping
  • A weak urine stream
  • Painful urination or urinary retention, leading to bladder infections or stones or kidney damage

Limitations of Current Treatments

Our market research suggests that as many as 36 million men in the United States are affected by BPH with approximately 5 million of these men suffering from bothersome symptoms. While 3 million men are prescribed pharmaceuticals for BPH in the US each year, these treatments lack sustainable efficacy and are associated with undesirable side effects including sexual dysfunction. With current pharmaceutical treatments, symptoms will usually return if medication is discontinued. More aggressive treatment options include invasive surgical procedures that may be successful at treating BPH. However, any type of prostate surgery can cause side effects, such as semen flowing backward into the bladder (retrograde ejaculation), loss of bladder control (incontinence) and impotence (erectile dysfunction). There is a demand for better balance between efficacy, safety and quality of life.

A Singular Solution

The lead drug candidate at Sophiris, PRX302 (topsalysin), is designed to be a single treatment for the long-term relief of BPH symptoms, without causing sexual dysfunction or sacrificing quality of life. Late stage development of PRX302 is supported by a successful randomized Phase IIb study (TRIUMPH) with standard and well defined regulatory endpoints. PRX302 has shown meaningful improvements in the International Prostate Symptom Score (IPSS) and urinary flow rate (Qmax) at 3, 6 and 12 months in this randomized, double-blind, placebo controlled Phase IIb trial (TRIUMPH). Prior to Phase III, 126 patients with BPH had been treated with PRX302, demonstrating an attractive safety profile including no drug-related erectile dysfunction adverse events. Enrollment into a Phase III clinical trial (PLUS 1) has been completed.

IPSS has been a primary endpoint and Qmax has been a secondary (or co-primary) endpoint for the FDA approval of currently available drugs for the treatment of BPH.

Learn more about clinical development of PRX302 in BPH here.